NasdaqGS - Delayed Quote USD

Insulet Corporation (PODD)

166.19 +2.02 (+1.23%)
At close: April 26 at 4:00 PM EDT
166.19 0.00 (0.00%)
After hours: April 26 at 5:32 PM EDT

Key Executives

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
NameTitlePayExercisedYear Born
Dr. James R. Hollingshead Ph.D. President, CEO & Director 2.88M -- 1963
Mr. Mark Field Senior VP & CTO 954.14k -- 1971
Mr. John Wodick Kapples Senior VP & General Counsel 1.02M -- 1960
Ms. Shacey Petrovic Director & Advisor 28.57k -- 1973
Mr. Eric Benjamin Executive VP, Chief Product & Customer Experience Officer 1.14M -- 1983
Mr. Prem Singh Senior Vice President of Global Operations -- -- 1977
Ms. Laetitia Cousin Senior VP of Regulatory Affairs, Quality Assurance & Compliance -- -- 1976
Angela Geryak Wiczek Senior Director of Corporate Communications -- -- --
Mr. Philip Hildale Senior Vice President of Sales & Customer Care -- -- --
Mr. Andrew Isaacson Senior VP of Strategy & Corporate Development -- -- --

Insulet Corporation

100 Nagog Park
Acton, MA 01720
United States
978 600 7000 https://www.insulet.com
Sector: 
Healthcare
Industry: 
Medical Devices
Full Time Employees: 
3,000

Description

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, the Middle East, Australia, and internationally. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.

Corporate Governance

Insulet Corporation’s ISS Governance QualityScore as of April 1, 2024 is 9. The pillar scores are Audit: 6; Board: 7; Shareholder Rights: 10; Compensation: 8.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Recent Events

Upcoming Events

May 09, 2024
Insulet Corporation Earnings Call

Related Tickers

TNDM Tandem Diabetes Care, Inc.
35.24
-0.90%
 
DXCM DexCom, Inc.
124.34
-9.91%
 
PEN Penumbra, Inc.
204.41
-0.53%
 
INSP Inspire Medical Systems, Inc.
237.45
+2.79%
 
EW Edwards Lifesciences Corporation
86.43
-1.80%
 
SWAV Shockwave Medical, Inc.
330.00
+0.31%
 
NARI Inari Medical, Inc.
38.42
+0.92%
 
MASI Masimo Corporation
136.14
+0.67%
 
ITGR Integer Holdings Corporation
109.58
-1.41%
 
ZBH Zimmer Biomet Holdings, Inc.
119.35
-0.33%